Thread by @ccleighton

Hybrid immunity comes at a cost - That aspect was missed from this editorial.
#LongCovid
Early Cardiovascular death.
Economic issues d/t illness, new-onset diabetes etc. & shrinking labour force.
One expert weighs in, Z. Chagla. 🙄

theglobeandmail.com/opinion/editor…

A failure in public health @JustinTrudeau :
"just over half of all Canadians have gotten a first booster and only 24 percent have gotten a second. That’s despite the fact that the National Advisory Council on Immunization recommends boosters six months after the previous dose."

That's nothing to celebrate
@CPHO_Canada @jyduclos @fordnation @SylviaJonesMPP
Less than 43% of Ontario children aged 5-11 have completed a primary series of mRNA vaccinations despite the known risks of diabetes and immune dysregulation - invasive Strep A, severe RSV etc.

That first booster reduces mortality by an additional 90% (Delta variant was prevalent).
@globeandmail could have done a better job with this editorial. It's not a case of one camp v. the other.
It should be, what does science tell us is the best approach?
nejm.org/doi/full/10.10…

And why have governments, media, and even some physicians pushed for an approach that strayed from the evidence?

And why do governments continue to ignore the importance of improving vaccine uptake?

#COVID19Ontario #cdnpoli #onpoli

Immunologically it makes sense to favour hybrid immunity, however, we would like to strongly caution against the conclusion that hybrid immunity should be a public health measure and people should not protect themselves from infection.. "
thelancet.com/journals/lanin…

"... or even be encouraged to acquire infection to gain superior hybrid immunity. Infection comes with risks, both during the acute phase and long-term, such as an increased cardiovascular risk or Long Covid."

"Unfortunately, the concept of hybrid immunity has become highly polarised, with some groups using it to argue against non-pharmaceutical interventions, such as mask wearing or isolation during active COVID-19."

"Such conclusions are misleading and risky, in particular, for people at high risk due to age or co-morbidities. Importantly, it also alienates the large group of people in low- and middle-income countries who have no access to any vaccines yet."